U.S. market Open. Closes in 5 hours 28 minutes

ABCL | AbCellera Biologics Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.1700 - 2.2600
52 Week Range 2.1100 - 4.75
Beta 0.56
Implied Volatility 103.58%
IV Rank 84.53%
Day's Volume 3,345,849
Average Volume 4,112,452
Shares Outstanding 297,988,000
Market Cap 664,513,240
Sector Healthcare
Industry Biotechnology
IPO Date 2020-12-11
Valuation
Profitability
Growth
Health
P/E Ratio -4.05
Forward P/E Ratio 18.56
EPS -0.55
1YR Price Target 28.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 586
Country Canada
Website ABCL
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
ABCL's peers: CWBR, HEPA, RAIN, KRYS, AVRO, CVAC, RETA, VIR, PPCB, PTCT, SRPT, IOVA, MDGL, CGC
*Chart delayed
Analyzing fundamentals for ABCL we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is very good and Health is weak. For more detailed analysis please see ABCL Fundamentals page.

Watching at ABCL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ABCL Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙